Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 26;24(1):98.
doi: 10.1186/s12890-024-02912-2.

Eosinophilic bronchiectasis increases length and cost of hospitalization: a retrospective analysis in a hospital of southern China from 2012 to 2020

Chengcheng Lei #  1   2 , Zhimin Zeng #  1   2 , Fengjia Chen  1   2 , Yubiao Guo  3   4 , Yangli Liu  5   6
Affiliations

Eosinophilic bronchiectasis increases length and cost of hospitalization: a retrospective analysis in a hospital of southern China from 2012 to 2020

Chengcheng Lei et al. BMC Pulm Med. .

Abstract

Background: The concept of eosinophilic bronchiectasis has received clinical attention recently, but the association between blood eosinophil count (BEC) and hospital characteristics has rarely been reported yet. We aim to investigate the clinical impact of BEC on patients with acute bronchiectasis exacerbation.

Methods: A total of 1332 adult patients diagnosed with acute exacerbation of bronchiectasis from January 2012 to December 2020 were included in this retrospective study. A propensity-matched analysis was performed by matching age, sex and comorbidities in patients with high eosinophil count (≥ 300 cell/µL) and low eosinophil count (< 300 cell/µL). Clinical characteristics, length of hospital stay (LOS), hospitalization cost and inflammatory markers were compared between the two groups.

Results: Eosinophilic bronchiectasis occurred in approximately 11.7% of all patients. 156 propensity score-matched pairs were identified with and without high eosinophil count. Eosinophilic bronchiectasis presented with a longer LOS [9.0 (6.0-12.5) vs. 5.0 (4.0-6.0) days, p < 0.0001] and more hospitalization cost [15,011(9,753-27,404) vs. 9,109(6,402-12,287) RMB, p < 0.0001] compared to those in non-eosinophilic bronchiectasis. The median white blood cell (WBC), lymphocyte, platelet (PLT) and C-reactive protein (CRP) levels in eosinophilic bronchiectasis were significantly increased. Multivariate logistic regression analysis confirmed that the high levels of eosinophil count (OR = 13.95, p < 0.0001), worse FEV1% predicted (OR = 7.80, p = 0.0003) and PLT (OR = 1.01, p = 0.035) were independent prognostic factors for length of hospital (LOS) greater than 7 days.

Conclusion: Eosinophilic bronchiectasis patients had longer length of hospital stay and more hospitalization cost compared to those in non-eosinophilic bronchiectasis group, which might be associated with the stronger inflammatory reaction.

Keywords: Blood eosinophil count; Bronchiectasis; Hospitalization cost; Inflammation markers; Length of hospital stay (LOS).

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flowchart of patient enrollment process. Abbreviations: EOS = Eosinophil count
Fig. 2
Fig. 2
Length of hospital stay in patients with eosinophilic bronchiectasis and non-eosinophilic bronchiectasis (A) and the correlation between blood eosinophil count and length of hospital stay (B) after propensity score matching. Abbreviations: Non-Eos BE = non-eosinophilic bronchiectasis; Eos BE = eosinophilic bronchiectasis
Fig. 3
Fig. 3
The correlation between blood eosinophil count and inflammatory marker after propensity score matching
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Chang AB, Fortescue R, Grimwood K, et al. European respiratory society guidelines for the management of children and adolescents with bronchiectasis. Eur Respir J. 2021;58(2):2002990. doi: 10.1183/13993003.02990-2020. - DOI - PubMed
    1. Chalmers JD, Elborn JS. Reclaiming the name 'bronchiectasis'. Thorax. 2015;70(5):399–400. doi: 10.1136/thoraxjnl-2015-206956. - DOI - PubMed
    1. Amati F, Simonetta E, Gramegna A, et al. The biology of pulmonary exacerbations in bronchiectasis. Eur Respir Rev. 2019;28(154):190055. doi: 10.1183/16000617.0055-2019. - DOI - PMC - PubMed
    1. Shoemark A, Cant E, Carreto L, et al. A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation. Eur Respir J. 2019;53(6):1900303. doi: 10.1183/13993003.00303-2019. - DOI - PubMed
    1. Giam YH, Shoemark A, Chalmers JD. Neutrophil dysfunction in bronchiectasis: an emerging role for immunometabolism. Eur Respir J. 2021;58(2):2003157. doi: 10.1183/13993003.03157-2020. - DOI - PubMed